DOCUMENT

NEUROLOGICAL FOUNDATION Funding was granted for research into a variety of conditions and purposes, including: • CONCUSSION • PARKINSON’SDISEASE • GLIOBLASTOMA • TINNITUS • SLEEPDISTURBANCE • HUNTINGTON’SDISEASE • CHARCOT-MARIE-TOOTH • EPILEPSY • COGNITIVE DECLINEWITHCRITICAL ILLNESS • MULTIPLE SCLEROSIS • STROKE • DEMENTIA • NEURODEVELOPMENTAL DISORDERS • HIGHGRADE GLIOMA • ALZHEIMER’SDISEASE • AUTOIMMUNE DISEASES • MIGRAINE AUDIT REPORT (Disclaimer): At the time of writing, Deloitte Limited has been unable to complete its annual audit of the financial statements of the Neurological Foundation of New Zealand. Market conditions around staffing and workloads mean Deloitte’s has delayed the audit for several months and will now be completing and finalising the audit during August/September 2022. In late October, an online version will be available on the Neurological Foundation website (neurological.org.nz) . This revised Annual Impact Report for 2021/2022 will include the signed-off Annual Audited Statements and Representation Letter. NUMBERS SNAPSHOT Please note these figures are unaudited NEARLY $5M was granted to neurological research in the past year – close to $1m more than the previous year 137 APPLICATIONS for funding were received 39 GRANTS were awarded $793KWAS GIVEN to increase stipends and to provide additional support for research affected by COVID-19 disruptions $2.5MWAS COMMITTED to funding the Neurological Foundation Chair of Clinical Neurology for the next five years until 2028 21DIGITALSEMINARS &13 IN-PERSON SEMINARS were held this year The Give the Green Light campaign raised approximately $480k from 2600 supporters 2